Effect of Overweight and Obesity on the Response to Anti-TNF Therapy and Disease Course in Children With IBD
Language English Country England, Great Britain Media print
Document type Journal Article, Multicenter Study
PubMed
39083286
DOI
10.1093/ibd/izae165
PII: 7724919
Knihovny.cz E-resources
- Keywords
- Crohn’s disease, adalimumab, infliximab, ulcerative colitis,
- MeSH
- Child MeSH
- Inflammatory Bowel Diseases * drug therapy complications MeSH
- Infliximab therapeutic use MeSH
- Humans MeSH
- Adolescent MeSH
- Overweight * complications MeSH
- Follow-Up Studies MeSH
- Obesity * complications MeSH
- Recurrence MeSH
- Retrospective Studies MeSH
- Risk Factors MeSH
- Tumor Necrosis Factor-alpha * antagonists & inhibitors MeSH
- Treatment Outcome MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Names of Substances
- Infliximab MeSH
- Tumor Necrosis Factor-alpha * MeSH
BACKGROUND: This study aimed to evaluate the effect of overweight and obesity at the start of anti-TNF therapy on treatment response and relapse rate in children with inflammatory bowel disease (IBD). METHODS: This multicenter, retrospective cohort study included 22 IBD centers in 14 countries. Children diagnosed with IBD in whom antitumor necrosis factor (anti-TNF) was introduced were included; those who were overweight/obese were compared with children who were well/undernourished. RESULTS: Six hundred thirty-seven children (370 [58%] males; mean age 11.5 ± 3.5 years) were included; 140 (22%) were in the overweight/obese group (OG) and 497 (78%) had BMI ≤1 SD (CG). The mean follow-up time was 141 ± 78 weeks (median 117 weeks). There was no difference in the loss of response (LOR) to anti-TNF between groups throughout the follow-up. However, children in OG had more dose escalations than controls. Male sex and lack of concomitant immunomodulators at the start of anti-TNF were risk factors associated with the LOR. There was no difference in the relapse rate in the first year after anti-TNF introduction; however, at the end of the follow-up, the relapse rate was significantly higher in the OG compared with CG (89 [64%] vs 218 [44%], respectively, P < .001). Univariate and multivariate analysis revealed that being overweight/obese, having UC, or being of male sex were factors associated with a higher risk for relapse. CONCLUSIONS: Overweight/obese children with IBD were not at a higher risk of LOR to anti-TNF. Relapse in the first year after anti-TNF was introduced, but risk for relapse was increased at the end of follow-up.
Overweight and obese children with inflammatory bowel disease required more frequent dose escalations, but overall loss of response to anti-TNF therapy was not increased. Furthermore, in the long term, they tend to have a higher risk for relapse.
Children's Hospital Zagreb University of Zagreb Medical School Zagreb Croatia
Department of Pediatrics School of Medicine Kyungpook National University Daegu Korea
DOCHAS Group Children's Health Ireland University College Dublin Dublin Ireland
Gastroenterology and Nutrition Unit Hospital Infantil Universitario Niño Jesús Madrid Spain
Gastroenterology and Nutrition Unit Meyer Children Hospital IRCCS Florence Italy
Heim Pal National Pediatric Institute Budapest Hungary
Institute for Maternal and Child Health IRCCS Burlo Garofolo Trieste Italy
Justus Liebig University Giessen Childrens Hospital Giessen Germany
Pediatric Department Children's Hospital Vittore Buzzi University of Milan Milan Italy
Pediatric Gastroenterology Unit Sapienza University Umberto 1 Hospital Rome Italy
University of Helsinki and Children´s Hospital HUS HelsinkiFinland
References provided by Crossref.org